Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations

References

• TeunissenCEMalekzadehALeursCBridelCKillesteinJBody fluid biomarkers for multiple sclerosis – the long road to clinical applicationNat Rev Neurol2015111058559626392381
   PubMed Web of Science ®Google Scholar
• WingerchukDMCarterJLMultiple sclerosis: current and emerging disease-modifying therapies and treatment strategiesMayo Clin Proc201489222524024485135
   PubMed Web of Science ®Google Scholar
• JonesDEGoldmanMDAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safetyExpert Rev Clin Immunol201410101281129125148422
   PubMed Web of Science ®Google Scholar
• KrumbholzMDerfussTHohlfeldRMeinlEB cells and antibodies in multiple sclerosis pathogenesis and therapyNat Rev Neurol201281161362323045237
   PubMed Web of Science ®Google Scholar
• Hill-CawthorneGAButtonTTuohyOLong term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosisJ Neurol Neurosurg Psychiatry201283329830422056965
   PubMed Web of Science ®Google Scholar
• ColesAJCoxALe PageEThe window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapyJ Neurol200625319810816044212
   PubMed Web of Science ®Google Scholar
• CossburnMDHardingKIngramGClinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosisNeurology2013801556123243077
   PubMed Web of Science ®Google Scholar
• ColesAJWingMGMolyneuxPMonoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosisAnn Neurol199946329630410482259
   PubMed Web of Science ®Google Scholar
• FoxEJSullivanHCGazdaSKA single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosisEur J Neurol201219230731121899662
   PubMed Web of Science ®Google Scholar
• HirstCLPaceAPickersgillTPCampath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosisJ Neurol2008255223123818283404
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet201238098561829183923122650
   PubMed Web of Science ®Google Scholar
• ColesAJCompstonDASelmajKWAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• TuohyOCostelloeLHill-CawthorneGAlemtuzumab treatment of multiple sclerosis: long-term safety and efficacyJ Neurol Neurosurg Psychiatry201586220821524849515
   PubMed Web of Science ®Google Scholar
• ColesAJFoxEVladicAAlemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trialNeurology201278141069107822442431
   PubMed Web of Science ®Google Scholar
• ColesAJHabekMBassADurable efficacy of alemtuzumab over 10 years: long-term follow-up of patients with RRMS from the CAMMS223 studyNeurology20168616P3.053
   Google Scholar
• GiovannoniGArnoldDLCohenJLong-term responders from the CARE-MS I study: no evidence of disease activity for 4 years following 2 courses of alemtuzumab and no further treatmentNeurology20168616P3.054
   Google Scholar
• WiendlHArnoldDLCohenJNo evidence of disease activity for 4 years following 2 courses of alemtuzumab and no further treatment: long-term responders from the CARE-MS II studyNeurology20168616P3.059
   Google Scholar
• RieraRPorfírioGJTorloniMRAlemtuzumab for multiple sclerosisCochrane Database Syst Rev20164CD01120327082500
   PubMedGoogle Scholar
• MengeTStüveOKieseierBCHartungH-PAlemtuzumab: the advantages and challenges of a novel therapy in MSNeurology2014831879724920854
   PubMed Web of Science ®Google Scholar
• HavrdovaEHorakovaDKovarovaIAlemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useTher Adv Neurol Disord201581314525584072
   PubMed Web of Science ®Google Scholar
• WillisMDHardingKEPickersgillTPAlemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohortMult Scler J201522912151223
   PubMed Web of Science ®Google Scholar
• CaonCMeyerCMayerLSmithMSEfficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing roleInt J MS Care201315415916824453779
   PubMedGoogle Scholar
• PenkertHDelbridgeCWantiaNWiestlerBKornTFulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosisJAMA Neurol201673675775927043129
   PubMed Web of Science ®Google Scholar
• IsidoroLPiresPRitoLCordeiroGProgressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumabBMJ Case Rep2014
   PubMedGoogle Scholar
• WaggonerJMartinuTPalmerSMProgressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplantJ Heart Lung Transplant200928439539819332268
   PubMed Web of Science ®Google Scholar
• JonesJLThompsonSAJLohPHuman autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferationProc Natl Acad Sci U S A201311050202002020524282306
   PubMed Web of Science ®Google Scholar
• DanielsGHVladicABrinarVAlemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosisJ Clin Endocrinol Metab2014991808924170099
   PubMed Web of Science ®Google Scholar
• CukerAStasiRPalmerJOyuelaP-MargolinDHBassASuccessful detection and management of immune thrombocytopenia in alemtuzumab-treated patients with active relapsing-remitting multiple sclerosisNeurology20148210 SupplP2.198
   Google Scholar
• AzzopardiLThompsonSAJHardingKEPredicting autoimmunity after alemtuzumab treatment of multiple sclerosisJ Neurol Neurosurg Psychiatry201485779579824368840
   PubMed Web of Science ®Google Scholar
• JonesJLPhuahC-LCoxALIL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)J Clin Invest200911972052206119546505
   PubMed Web of Science ®Google Scholar
• ObermannMRuckTPfeufferSBaumJWiendlHMeuthSGSimultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosisMult Scler20162291235124126980848
   PubMed Web of Science ®Google Scholar
• LerayEYaouanqJLe PageEEvidence for a two-stage disability progression in multiple sclerosisBrain J Neurol2010133Pt 719001913
   Google Scholar
• TintoreMRoviraÀRíoJDefining high, medium and low impact prognostic factors for developing multiple sclerosisBrain2015138Pt 71863187425902415
   PubMed Web of Science ®Google Scholar
• ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disabilityBrain J Neurol2010133Pt 719141929
   Google Scholar
• ScalfariANeuhausADaumerMEbersGCMuraroPAAge and disability accumulation in multiple sclerosisNeurology201177131246125221917763
   PubMed Web of Science ®Google Scholar
• SormaniMPArnoldDLDe StefanoNTreatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosisAnn Neurol2014751434924006277
   PubMed Web of Science ®Google Scholar
• WattjesMPRoviraÀMillerDEvidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – establishing disease prognosis and monitoring patientsNat Rev Neurol2015111059760626369511
   PubMed Web of Science ®Google Scholar